Literature DB >> 1235061

Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man: a preliminary report.

O Almersjö, A Brandberg, B Gustavsson.   

Abstract

5-Fluorouracil (5-FU) was administered to 8 patients with malignant liver tumours either by regional portal or general intravenous infusion. During continuous portal infusion of 15 mg 5-FU/kg/24 h, systemic serum-concentrations were generally below 100 ng/ml and no side-effects were seen. Intravenous infusion of the same dose was accompanied by serum-concentrations above 100 ng/ml and bone-marrow depression. This preliminary study indicates that there are better prerequisites for high anti-toumour effect and low frequency of side-effects during portal infusion of 5-FU than during general intravenous administration to patients with liver tumours.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1235061     DOI: 10.1016/s0304-3835(75)95831-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  EORTC trials in large bowel cancer.

Authors:  A Gerard; J L Berrod; J Loygue
Journal:  Int J Colorectal Dis       Date:  1986-04       Impact factor: 2.571

2.  Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality.

Authors:  U Metzger; B Mermillod; P Aeberhard; F Gloor; A Bissat; R Egeli; U Laffer; S Martinoli; W Mueller; R Schroeder
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 3.  Intraportal chemotherapy for colorectal hepatic metastases.

Authors:  U T Laffer; U Metzger
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.

Authors:  N Greenberg; D E Schumm; T E Webb
Journal:  Biochem J       Date:  1977-05-15       Impact factor: 3.857

Review 5.  Adjuvant therapy for colorectal carcinoma.

Authors:  U Metzger
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.